Rosendaal FR - Search Results

1

Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.

Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Stegeman BH, et al. Among authors: rosendaal fr. BMJ. 2013 Sep 12;347:f5298. doi: 10.1136/bmj.f5298. BMJ. 2013. PMID: 24030561 Free PMC article. Review.

2

More objective diagnoses of venous thromboembolism?

Koster T, Rosendaal FR, van der Meer FJ, Briët E, Vandenbroucke JP. Koster T, et al. Among authors: rosendaal fr. Neth J Med. 1991 Jun;38(5-6):246-8. Neth J Med. 1991. PMID: 1922597

3

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.

Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Bloemenkamp KW, et al. Among authors: rosendaal fr. Lancet. 1995 Dec 16;346(8990):1593-6. doi: 10.1016/s0140-6736(95)91929-5. Lancet. 1995. PMID: 7500751

4

Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties.

Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Koster T, et al. Among authors: rosendaal fr. J Intern Med. 1995 Jul;238(1):31-7. doi: 10.1111/j.1365-2796.1995.tb00896.x. J Intern Med. 1995. PMID: 7608644

5

Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study).

Koster T, Rosendaal FR, Briët E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Koster T, et al. Among authors: rosendaal fr. Blood. 1995 May 15;85(10):2756-61. Blood. 1995. PMID: 7742536 Free article.

6

Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.

Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Koster T, et al. Among authors: rosendaal fr. Lancet. 1995 Jan 21;345(8943):152-5. doi: 10.1016/s0140-6736(95)90166-3. Lancet. 1995. PMID: 7823669

7

Anticoagulation: how low can one go?

Rosendaal FR. Rosendaal FR. Lancet. 1994 Apr 9;343(8902):867-8. doi: 10.1016/s0140-6736(94)90003-5. Lancet. 1994. PMID: 7908353 No abstract available.

8

Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.

Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Vandenbroucke JP, et al. Among authors: rosendaal fr. Lancet. 1994 Nov 26;344(8935):1453-7. doi: 10.1016/s0140-6736(94)90286-0. Lancet. 1994. PMID: 7968118 Free article.

9

A method to determine the optimal intensity of oral anticoagulant therapy.

Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. Rosendaal FR, et al. Thromb Haemost. 1993 Mar 1;69(3):236-9. Thromb Haemost. 1993. PMID: 8470047

10

Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation.

Manten B, Westendorp RG, Koster T, Reitsma PH, Rosendaal FR. Manten B, et al. Among authors: rosendaal fr. Thromb Haemost. 1996 Oct;76(4):510-3. Thromb Haemost. 1996. PMID: 8902987

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results